Cargando…

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

Our objective was to assess the 5-year cost effectiveness of bronchodilator therapy with tiotropium, salmeterol or ipratropium for chronic obstructive pulmonary disease (COPD) from the perspective of the Spanish National Health System (NHS). A probabilistic Markov model was designed wherein patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rutten-van Mölken, Maureen P. M. H., Oostenbrink, Jan B., Miravitlles, Marc, Monz, Brigitta U.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2007
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1913175/ https://www.ncbi.nlm.nih.gov/pubmed/17370096 http://dx.doi.org/10.1007/s10198-007-0039-4

Ejemplares similares

Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
por: Naik, Shalini, et al.
Publicado: (2010)

Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(®) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy
por: Selya-Hammer, Carl, et al.
Publicado: (2016)

Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease
por: Halpern, Rachel, et al.
Publicado: (2011)

Sequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice setting
por: Gauhar, Umair, et al.
Publicado: (2009)

Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease
por: Chatterjee, Arjun, et al.
Publicado: (2012)

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations
por: Beeh, Kai-Michael, et al.
Publicado: (2009)

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
por: Anzueto, Antonio, et al.
Publicado: (2020)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
por: Tamura, Tomohiro, et al.
Publicado: (2016)

Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation
por: Sunwoo, Jung, et al.
Publicado: (2017)

Ipratropium bromide is more effective than Salmeterol — Fluticason combination on O(2) saturation patients with COPD
por: Rezaie, Nader, et al.
Publicado: (2013)

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
por: Hodder, Richard, et al.
Publicado: (2007)

Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study
por: Hoogendoorn, Martine, et al.
Publicado: (2021)

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results
por: Hoogendoorn, Martine, et al.
Publicado: (2019)

Adjusting for COPD severity in database research: developing and validating an algorithm
por: Goossens, Lucas MA, et al.
Publicado: (2011)

Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease
por: Miravitlles, Marc, et al.
Publicado: (2015)

Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients
por: Beier, Jutta, et al.
Publicado: (2012)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK
por: Eklund, Oskar, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease
por: Hohlfeld, JM, et al.
Publicado: (2014)

Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®)
por: Vogelmeier, Claus F., et al.
Publicado: (2015)

Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease
por: Li, Xuan, et al.
Publicado: (2017)

The Effect of Ipratropium Bromide with Violet Flower Extract, Ipratropium Bromide with Budesonide, and Ipratropium Bromide Alone on the Cuff-Leak of the Endotracheal Tube in Intubated ICU Patients
por: Hashemi, Seyed Taghi, et al.
Publicado: (2023)

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
por: Herth, Felix, et al.
Publicado: (2020)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
por: Kalhan, Ravi, et al.
Publicado: (2021)

Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China
por: Lan, Ying, et al.
Publicado: (2022)

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
por: Miravitlles, Marc, et al.
Publicado: (2016)

Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease
por: Panos, Ralph J
Publicado: (2013)

Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: a cost-effectiveness analysis
por: van Boven, Job FM, et al.
Publicado: (2014)

Bromangiomas-ipratropium bromide–associated angiomas
por: Samlaska, Curt, et al.
Publicado: (2019)

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
por: Ohar, Jill A, et al.
Publicado: (2014)

The Combination of Tiotropium and Budesonide in the Treatment of Chronic Obstructive Pulmonary Disease
por: Um, Sang-Won, et al.
Publicado: (2007)

Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease
por: Koser, Andras, et al.
Publicado: (2010)

Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma
por: Alvarado-Gonzalez, Alcibey, et al.
Publicado: (2015)

Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden
por: Eklund, Oskar, et al.
Publicado: (2015)

The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease
por: Gong, Yinhua, et al.
Publicado: (2022)

Predictors of Pulmonary Function Response to Treatment with Salmeterol/fluticasone in Patients with Chronic Obstructive Pulmonary Disease
por: Lee, Jae Seung, et al.
Publicado: (2011)

The Acute Effects of the Use of Salbutamol and Ipratropium on the Heart Rates of Patients With Obstructive Airway Disease
por: Akhtar, Ayesha, et al.
Publicado: (2023)

Use of inhaled ipratropium bromide to improve exercise-induced laryngeal obstruction cannot be recommended
por: Muralitharan, Praveen, et al.
Publicado: (2023)

Effects of Ipratropium Bromide Combined with Traditional Chinese Medicine Intervention on the Pulmonary Function and Psychological Status of Patients with Chronic Obstructive Pulmonary Disease
por: Ye, Wen-Yi, et al.
Publicado: (2023)

How to Address Uncertainty in Health Economic Discrete-Event Simulation Models: An Illustration for Chronic Obstructive Pulmonary Disease
por: Corro Ramos, Isaac, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8lf6u7f47j99db83m2hh01hsmb